Earlier this year, we announced top-line results from the Phase 1 healthy volunteer trial of our wild-type KIT inhibitor. Just a few months later, we've initiated two out of four clinical proof-of-concept studies planned for this year, including in chronic urticaria.

We're celebrating 2 years since the U.S. FDA approval of our indolent systemic mastocytosis treatment. As we build on our proven expertise, we're committed to driving continued innovation in systemic mastocytosis and other allergic/inflammatory disorders: bit.ly/4j8K89T

We’re pleased to share that Tanya Green has been appointed our new Senior Vice President, Chief of Staff, reflecting her continued leadership in shaping our company’s future. Tanya brings deep expertise and a passion for impact to our business and our culture.

We are pleased to share that we have reached an agreement to become part of Sanofi, a global leader in rare disease and immunology. Please refer to today’s full announcement for key information and cautionary statements: bit.ly/4kpAyky

At #EHA2025 & #EAACI2025, we’re sharing data reinforcing the real-world burden of systemic mastocytosis (SM) & the high unmet needs across the spectrum of disease. We’re committed to working with leading experts to transform SM care in Europe. Read more: bit.ly/4n0IzxQ

At #EAACI2025, we shared insights on the socio-emotional impacts across the spectrum of indolent systemic mastocytosis (ISM) based on results from our PRISM Survey, one of the largest studies characterizing the impact of SM from both patient and clinical perspectives. Learn more:

When treating serious diseases, prognostic scoring systems help physicians adapt treatment based on a patient's risk of disease progression. At #EHA2025, we shared data on our Revised Mutation-Adjusted Risk Score, evaluating unique risk factors for advanced systemic mastocytosis.

We recently announced the initiation of a proof-of-concept study in Allergic Rhinoconjunctivitis, following results from the Phase 1 healthy volunteer trial of our wild-type KIT inhibitor and marking one of our first proof-of-concept study initiations this year. Learn more:

Advancing patient outcomes relies on more than clinical data alone – it also involves integrating patient insights from the start. We develop patient-reported outcomes tools as an approach to assess treatment benefit & real-world disease burden. Read more: bluprnt.info/4kvrbQk

We're dedicated to improving systemic mastocytosis care by focusing on what matters most to patients. In collaboration with experts and the community, we've developed SM-specific PRO measures to help us better understand patient experiences. Read more: bluprnt.info/4kvrbQk

We are proud to begin our next chapter as part of @Sanofi, a global leader in rare disease and immunology. Together, we believe we can deliver on our joint mission to bring life-changing medicines to many more patients worldwide. Read the press release: bit.ly/3GP5ITU

We're proud that data from our PRISM Survey, Europe’s largest study on the impact of systemic mastocytosis, has been published in Clinical & Experimental Allergy. These results highlight the disease’s daily impact and need for awareness. Learn more: bluprnt.info/3U7RBfz

At Blueprint Medicines, a Sanofi company, we’re pioneers in mast cell biology, driven by a commitment to scientific innovation. By targeting the root causes of difficult-to-treat diseases like mast cell disorders, we aim to deliver meaningful therapies and improve patients' lives

Since our founding, we worked at the intersection of scientific innovation and operational excellence. Now as Blueprint Medicines, a Sanofi company, we have never been more ready to expand our reach, accelerate innovation and deliver more for patients in need.

Diagnosing systemic mastocytosis can take ~6 years due to heterogenous symptoms often mimicking other diseases. Read how we're using artificial intelligence to help improve SM care in the future: bit.ly/46D3y4j

Systemic mastocytosis often hides in plain sight, with non-specific symptoms manifesting across organ systems and prolonging time to diagnosis. By helping clinicians recognize SM's signs and symptoms earlier, we aim to shorten the diagnostic journey and improve patient care.

At #EADVcongress, we look forward to sharing how we’re harnessing artificial intelligence to better understand skin symptoms in patients with ISM. By leveraging AI and other technologies, we’re committed to advancing innovation and shaping the future of patient care.

Symptom burden often prompts people with ISM to seek care, but measuring it is difficult due to varied symptoms and gaps in perception of disease control between patients and doctors. We work to raise awareness of ISM and tools that measure symptom burden to improve patient care:

Our dedication to mast cell disease research is driven by our goal to address important needs for patients globally. From understanding mast cell biology to delivering our medicine for systemic mastocytosis, we’re now working to expand our research to reach more patients. #MCAD

MastoConnect, our new platform for the systemic mastocytosis (SM) community, is now live. Designed with the community in mind, this website brings together patient stories, disease education and resources all in one place. Visit: mastoconnect.com